Rhenman & Partners Asset Management Ab Increased Portola Pharmaceuticals Inc (NASDAQ:PTLA) Stake by $10.08 Million

October 13, 2017 - By Stephen Andrade

Investors sentiment decreased to 1.31 in Q2 2017. Its down 0.29, from 1.6 in 2017Q1. It dropped, as 17 investors sold PTLA shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. Hall Laurie J Trustee holds 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 190 shares. Arrowstreet Limited Partnership has invested 0.01% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Federated Invsts Inc Pa invested 0.01% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Tourbillon Cap Ptnrs Lp owns 198,903 shares. Brown Advisory Incorporated holds 8,770 shares. Financial Bank Of Montreal Can invested in 0% or 535 shares. Paradigm Asset Mgmt Com Ltd Com owns 11,800 shares. Blair William And Company Il, Illinois-based fund reported 31,600 shares. 15,210 are owned by Jacobs Levy Equity Mgmt Inc. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 2,078 shares or 0% of the stock. California State Teachers Retirement Systems has 0.01% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 88,055 shares. Partner Inv L P owns 52,269 shares. Invesco Limited holds 0% or 145,066 shares in its portfolio. Captrust Advisors accumulated 300 shares or 0% of the stock. Endurant Cap Mgmt Limited Partnership owns 19,200 shares.

Since May 31, 2017, it had 1 buy, and 1 insider sale for $54.68 million activity. Shares for $58.48 million were sold by Maxwell (Mauritius) Pte Ltd on Thursday, June 1.

Rhenman & Partners Asset Management Ab increased its stake in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 168.4% based on its latest 2017Q3 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab bought 186,595 shares as the company’s stock rose 22.73% with the market. The institutional investor held 297,400 shares of the health care company at the end of 2017Q3, valued at $16.07 million, up from 110,805 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be bullish on the $3.30 billion market cap company. The stock decreased 3.51% or $1.87 during the last trading session, reaching $51.42. About 735,146 shares traded. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 51.17% since October 14, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

Portola Pharmaceuticals Inc (NASDAQ:PTLA) Ratings Coverage

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharmaceuticals has $81 highest and $24 lowest target. $68.17’s average target is 32.57% above currents $51.42 stock price. Portola Pharmaceuticals had 28 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) has “Buy” rating given on Wednesday, August 5 by Cowen & Co. The rating was initiated by Goldman Sachs on Friday, December 18 with “Buy”. The firm has “Buy” rating by Citigroup given on Tuesday, January 3. On Friday, February 24 the stock rating was upgraded by Oppenheimer to “Outperform”. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) has “Neutral” rating given on Friday, August 19 by Credit Suisse. The stock has “Outperform” rating by Credit Suisse on Thursday, August 24. Oppenheimer maintained the shares of PTLA in report on Monday, June 26 with “Buy” rating. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) has “Outperform” rating given on Monday, March 28 by Credit Suisse. The company was maintained on Wednesday, September 20 by Credit Suisse. The rating was maintained by Cowen & Co with “Buy” on Monday, June 26.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $3.30 billion. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. It currently has negative earnings. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

More recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Seekingalpha.com which released: “Expect A Slow Bleed With Portola Pharma” on September 22, 2017. Also Seekingalpha.com published the news titled: “Portola – A High-Risk, High-Return Investment Opportunity” on September 21, 2017. Globenewswire.com‘s news article titled: “Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise …” with publication date: October 11, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.